1. Home
  2. ARBE vs BMEA Comparison

ARBE vs BMEA Comparison

Compare ARBE & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbe Robotics Ltd.

ARBE

Arbe Robotics Ltd.

HOLD

Current Price

$0.70

Market Cap

79.1M

Sector

Technology

ML Signal

HOLD

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.20

Market Cap

91.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARBE
BMEA
Founded
2015
2017
Country
Israel
United States
Employees
144
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.1M
91.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
ARBE
BMEA
Price
$0.70
$1.20
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$2.38
$9.83
AVG Volume (30 Days)
1.4M
636.9K
Earning Date
05-19-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.19
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$363.94
N/A
Revenue Next Year
$286.43
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$0.87
52 Week High
$2.88
$2.99

Technical Indicators

Market Signals
Indicator
ARBE
BMEA
Relative Strength Index (RSI) 46.37 39.14
Support Level $0.65 $1.05
Resistance Level $0.90 $1.44
Average True Range (ATR) 0.06 0.06
MACD -0.00 -0.01
Stochastic Oscillator 39.33 30.23

Price Performance

Historical Comparison
ARBE
BMEA

About ARBE Arbe Robotics Ltd.

Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles as well as for non-automotive uses. Its geographical segments include Sweden, China, Germany, Hong Kong, USA, Israel, Switzerland, Italy, and others.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: